[1]栗怡然,朱瑞琳,杨柳.炎症在视网膜静脉阻塞性黄斑水肿中的作用[J].眼科新进展,2020,40(1):090-94.[doi:10.13389/j.cnki.rao.2020.0023]
　LI Yiran,ZHU Ruilin,YANG Liu.Role of inflammation in macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2020,40(1):090-94.[doi:10.13389/j.cnki.rao.2020.0023]
点击复制

炎症在视网膜静脉阻塞性黄斑水肿中的作用/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年1期
页码:
090-94
栏目:
文献综述
出版日期:
2020-01-05

文章信息/Info

Title:
Role of inflammation in macular edema secondary to retinal vein occlusion
文章编号:
20200123
作者:
栗怡然; 朱瑞琳; 杨柳
100034　北京市，北京大学第一医院眼科
Author(s):
LI Yiran; ZHU Ruilin; YANG Liu
Department of Ophthalmology,the Peking University First Hospital,Beijing 100034,China
Corresponding author:YANG Liu,E-mail:liu_yang@bjmu.edu.cn
关键词:
视网膜静脉阻塞; 黄斑水肿; 炎症
Keywords:
retinal vein occlusion; macular edema; inflammation
分类号:
R774
DOI:
10.13389/j.cnki.rao.2020.0023
文献标志码:
R
摘要:
视网膜静脉阻塞性黄斑水肿是造成患者视力下降及致盲的常见原因。研究表明，炎症机制在黄斑水肿的发生过程中发挥了重要作用。视网膜静脉阻塞发生后，局部损伤激活固有免疫活性细胞，合成和释放大量细胞因子，共同参与炎症反应，导致黄斑水肿发生。本文就视网膜静脉阻塞继发黄斑水肿可能的炎症机制作一综述，以期为针对炎症的治疗提供理论依据。
Abstract:
Macular edema secondary to retinal vein occlusion is a common reason of visual loss and blindness.Studies have shown that inflammation plays a significant role in the development of macular edema.After the occurrence of retinal vein occlusion，local injury activates resident immune competent cells,promotes synthesis and release of cytokines，and involves in inflammathory response,which contributes to macular edema.The article reviews the mechanism of inflammation in macular edema secondary to retinal vein occlusion，in order to provide the theoretical basis for treatment of inflammation.

参考文献/References:

［1］　WONG T Y，SCOTT I U.Clinical practice.Retinal-vein occlusion［J］.N Engl J Med，2010，363（22）：2135-2144.
［2］　ROGERS S，MCINTOSH R L，CHEUNG N，LIM L，WANG J J，MITCHELL P，et al.The prevalence of retinal vein occlusion：pooled data from population studies from the United States，Europe，Asia，and Australia［J］.Ophthalmology，2010，117（2）：313-319.e311.
［3］　张惠蓉，夏英杰.视网膜静脉阻塞患者视力预后相关因素分析［J］.中华眼科杂志，2002，38（2）：98-102.
ZHANG H R，XIA Y J.Analysis of visual prognosis and correlative factors in retinal vein occlusion［J］.Chin J Ophthalmol，2002，38（2）：98-102.
［4］　DARUICH A，MATET A，MOULIN A，KOWALCZUK L，NICOLAS M，SELLA M A，et al.Mechanisms of macular edema：Beyond the surface［J］.Prog Retin Eye Res，2018，63：20-68.
［5］　BAARTMAN BJ，GANS R，GOSHE J.Prednisolone versus dexamethasone for prevention of pseudophakic cystoid macular edema［J］.Can J Ophthalmol，2018，53（2）：131-134.
［6］　LO GIUDICE G，AVARELLO A，CAMPANA G，GALAN A.Rapid response to dexamethasone intravitreal implant in diabetic macular edema［J］.Eur J Ophthalmol，2018，28（1）：74-79.
［7］　BERASATEGUI B，FONOLLOSA A，ARTARAZ J，RUIZ-ARRUZA I，RIOS J，MATAS J，et al.Behavior of hyperreflective foci in non-infectious uveitic macular edema，a 12-month follow-up prospective study［J］.BMC Ophthalmol，2018，18（1）：179.
［8］　YOSHIDA S，YOSHIDA A，ISHIBASHI T.Induction of IL-8，MCP-1，and bFGF by TNF-α in retinal glial cells：implications for retinal neovascularization during post-ischemic inflammation［J］.Graefes Arch Clin Exp Ophthalmol，2004，242（5）：409-413.
［9］　EBNETER A，KOKONA D，SCHNEIDER N，ZINKERNAGEL M S.Microglia activation and recruitment of circulating macrophages during ischemic experimental branch retinal vein occlusion［J］.Invest Ophthalmol Vis Sci，2017，58（2）：944-953.
［10］　DELL’OMO R，SEMERARO F，BAMONTE G，CIFARIELLO F，ROMANO M R，COSTAGLIOLA C.Vitreous mediators in retinal hypoxic diseases［J］.Mediators Inflamm，2013，2013：935301.
［11］　ASCASO F J，HUERVA V，GRZYBOWSKI A.The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases［J］.Mediators Inflamm，2014，2014：432685.
［12］　SCHOLL S，KIRCHHOF J，AUGUSTIN A J.Pathophysiology of macular edema［J］.Ophthalmologica，2010，224 Suppl 1：8-15.
［13］　AL-JANABI A，LIGHTMAN S，TOMKINS-NETZER O.“Statins in retinal disease”［J］.Eye （Lond），2018，32（5）：981-991.
［14］　WANG W，LO A C Y.Diabetic retinopathy：pathophysiology and treatments［J］.Int J Mol Sci，2018，19（6）：1816.
［15］　ARROBA A I，VALVERDE A M.Modulation of microglia in the retina：new insights into diabetic retinopathy［J］.Acta Diabetol，2017，54（6）：527-533.
［16］　NATOLI R，FERNANDO N，MADIGAN M，CHU-TAN J A，VALTER K，PROVIS J，et al.Microglia-derived IL-1beta promotes chemokine expression by Muller cells and RPE in focal retinal degeneration［J］.Mol Neurodegener，2017，12（1）：31.
［17］　WANG M，WONG W T.Microglia-Muller cell interactions in the retina［J］.Adv Exp Med Biol，2014，801：333-338.
［18］　GRIGSBY J G，CARDONA S M，POUW C E，MUNIZ A，MENDIOLA A S，TSIN A T，et al.The role of microglia in diabetic retinopathy［J］.J Ophthalmol，2014，2014：705783.
［19］　REHAK M，HOLLBORN M，IANDIEV I，PANNICKE T，KARL A，WURM A，et al.Retinal gene expression and Muller cell responses after branch retinal vein occlusion in the rat［J］.Invest Ophthalmol Vis Sci，2009，50（5）：2359-2367.
［20］　PURO D G，STUENKEL E L.Thrombin-induced inhibition of potassium currents in human retinal glial （Muller） cells［J］.J Physiol，1995，485 （Pt 2）：337-348.
［21］　NICCHIA G P，PISANI F，SIMONE L，CIBELLI A，MOLA M G，DAL MONTE M，et al.Glio-vascular modifications caused by Aquaporin-4 deletion in the mouse retina［J］.Exp Eye Res，2016，146：259-268.
［22］　LIU X，YE F，XIONG H，HU D N，LIMB G A，XIE T，et al.IL-1beta induces IL-6 production in retinal Muller cells predominantly through the activation of p38 MAPK/NF-kappaB signaling pathway［J］.Exp Cell Res，2015，331（1）：223-231.
［23］　RUTAR M，NATOLI R，CHIA R X，VALTER K，PROVIS J M.Chemokine-mediated inflammation in the degenerating retina is coordinated by Muller cells，activated microglia，and retinal pigment epithelium［J］.J Neuroinflammat，2015，12：8.
［24］　WILKINSON-BERKA J L，MILLER AG，BINGER K J.Prorenin and the （pro）renin receptor：recent advances and implications for retinal development and disease［J］.Curr Opin Nephrol Hypertens，2011，20（1）：69-76.
［25］　BRINGMANN A，WIEDEMANN P.Muller glial cells in retinal disease［J］.Ophthalmologica，2012，227（1）：1-19.
［26］　ARJAMAA O，AALTONEN V，PIIPPO N，CSONT T，PETROVSKI G，KAARNIRANTA K，et al.Hypoxia and inflammation in the release of VEGF and interleukins from human retinal pigment epithelial cells［J］.Graefes Arch Clin Exp Ophthalmol，2017，255（9）：1757-1762.
［27］　WANG K，ZHU X，ZHANG K，YAO Y，ZHUANG M，TAN C，et al.Puerarin inhibits amyloid beta-induced NLRP3 inflammasome activation in retinal pigment epithelial cells via suppressing ROS-dependent oxidative and endoplasmic reticulum stresses［J］.Exp Cell Res，2017，357（2）：335-340.
［28］　SHIEH C H，HEINRICH A，SERCHOV T，VAN CALKER D，BIBER K.P2X7-dependent，but differentially regulated release of IL-6，CCL2，and TNF-alpha in cultured mouse microglia［J］.Glia，2014，62（4）：592-607.
［29］　OMRI S，BEHAR-COHEN F，DE KOZAK Y，SENNLAUB F，VERISSIMO L M，JONET L，et al.Microglia/macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy：role of PKCzeta in the Goto Kakizaki rat model［J］.Am J Pathol，2011，179（2）：942-953.
［30］　NOMA H，MIMURA T，SHIMADA K.Role of inflammation in previously untreated macular edema with branch retinal vein occlusion［J］.BMC Ophthalmol，2014，14：67.
［31］　NOMA H，FUNATSU H，MIMURA T，EGUCHI S.Vitreous inflammatory factors and serous retinal detachment in central retinal vein occlusion：a case control series［J］.J Inflamm （Lond），2011，8：38.
［32］　REICH M，DACHEVA I，NOBL M，SIWY J，SCHANSTRA J P，MULLEN W，et al.Proteomic analysis of vitreous humor in retinal vein occlusion［J］.PLoS One，2016，11（6）：e0158001.
［33］　SCHRAUFSTATTER I U，TRIEU K，SIKORA L，SRIRAMARAO P，DISCIPIO R.Complement c3a and c5a induce different signal transduction cascades in endothelial cells［J］.J Immunol，2002，169（4）：2102-2110.
［34］　NOMA H，FUNATSU H，MIMURA T，HARINO S，HORI S.Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion［J］.Eur J Ophthalmol，2010，20（2）：402-409.
［35］　DEREVJANIK N L，VINORES S A，XIAO W H，MORI K，TURON T，HUDISH T，et al.Quantitative assessment of the integrity of the blood-retinal barrier in mice［J］.Invest Ophthalmol Vis Sci，2002，43（7）：2462-2467.
［36］　AVELEIRA C A，LIN C M，ABCOUWER S F，AMBROSIO A F，ANTONETTI D A.TNF-alpha signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeability［J］.Diabetes，2010，59（11）：2872-2882.
［37］　PENFOLD P L，WEN L，MADIGAN M C，KING N J，PROVIS J M.Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells［J］.Invest Ophthalmol Vis Sci，2002，43（9）：3125-3130.
［38］　SHIRASAWA M，SONODA S，TERASAKI H，ARIMURA N，OTSUKA H，YAMASHITA T，et al.TNF-alpha disrupts morphologic and functional barrier properties of polarized retinal pigment epithelium［J］.Exp Eye Res，2013，110：59-69.
［39］　CLAUDIO L，MARTINEY J A，BROSNAN C F.Ultrastructural studies of the blood-retina barrier after exposure to interleukin-1 beta or tumor necrosis factor-alpha［J］.Lab Invest，1994，70（6）：850-861.
［40］　BEHL Y，KROTHAPALLI P，DESTA T，DIPIAZZA A，ROY S，GRAVES D T.Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy［J］.Am J Pathol，2008，172（5）：1411-1418.
［41］　FENG J，ZHAO T，ZHANG Y，MA Y，JIANG Y.Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion［J］.PLoS One，2013，8（7）：e68149.
［42］　ROSENBAUM J T，SAMPLES J R，HEFENEIDER S H，HOWES E L.Ocular inflammatory effects of intravitreal interleukin 1［J］.Arch Ophthalmol，1987，105（8）：1117-1120.
［43］　VINORES S A，XIAO W H，ZIMMERMAN R，WHITCUP S M，WAWROUSEK E F.Upregulation of vascular endothelial growth factor （VEGF） in the retinas of transgenic mice overexpressing interleukin-1beta （IL-1beta） in the lens and mice undergoing retinal degeneration［J］.Histol Histopathol，2003，18（3）：797-810.
［44］　WILLIAMS M R，KATAOKA N，SAKURAI Y，POWERS C M，ESKIN S G，MCINTIRE L V.Gene expression of endothelial cells due to interleukin-1 beta stimulation and neutrophil transmigration［J］.Endothelium，2008，15（1）：73-84.
［45］　JUNG S H，KIM K A，SOHN S W，YANG S J.Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion［J］.Invest Ophthalmol Vis Sci，2014，55（4）：2290-2296.
［46］　ROCHFORT K D，COLLINS L E，MURPHY R P，CUMMINS P M.Downregulation of blood-brain barrier phenotype by proinflammatory cytokines involves NADPH oxidase-dependent ROS generation：consequences for interendothelial adherens and tight junctions［J］.PLoS One，2014，9（7）：e101815.
［47］　NOMA H，MIMURA T，YASUDA K，SHIMURA M.Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema［J］.Invest Ophthalmol Vis Sci，2015，56（2）：1122-1128.
［48］　FONOLLOSA A，GARCIA-ARUMI J，SANTOS E，MACIA C，FERNANDEZ P，SEGURA R M，et al.Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion［J］.Eye （Lond），2010，24（7）：1284-1290.
［49］　YU H，HUANG X，MA Y，GAO M，WANG O，GAO T，et al.Interleukin-8 regulates endothelial permeability by down-regulation of tight junction but not dependent on integrins induced focal adhesions［J］.Int J Biol Sci，2013，9（9）：966-979.
［50］　PETREACA ML，YAO M，LIU Y，DEFEA K，MARTINS-GREEN M.Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 （IL-8/CXCL8） is required for IL-8/CXCL8-induced endothelial permeability［J］.Mol Biol Cell，2007，18（12）：5014-5023.
［51］　YENIHAYAT F，OZKAN B，KASAP M，KARABAS V L，GUZEL N，AKPINAR G，et al.Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid［J］.Int Ophthalmol，2018，39（4）：821-828.
［52］　黄银花，叶波.糖尿病性黄斑水肿与炎症［J］.国际眼科纵览，2017，41（1）：62-67.
HUANG Y H，YE B.The relationship between diabetic macular edema and inflammation［J］.Int J Ophthalmol，2017，41（1）：62-67.
［53］　YOSHIDA A，ELNER S G，BIAN Z M，KUNKEL S L，LUKACS N W，ELNER V M.Thrombin regulates chemokine induction during human retinal pigment epithelial cell/monocyte interaction［J］.Am J Pathol，2001，159（3）：1171-1180.
［54］　STAMATOVIC S M，KEEP R F，KUNKEL S L，ANDJELKOVIC A V.Potential role of MCP-1 in endothelial cell tight junction “opening”：signaling via Rho and Rho kinase［J］.J Cell Sci，2003，116（Pt 22）：4615-4628.
［55］　MOON S W，SUN Y，WARTHER D，HUFFMAN K，FREEMAN W R，SAILOR M J，et al.New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies［J］.Drug Deliv，2018，25（1）：600-610.
［56］　LUNA J D，CHAN C C，DEREVJANIK N L，MAHLOW J，CHIU C，PENG B，et al.Blood-retinal barrier （BRB） breakdown in experimental autoimmune uveoretinitis：comparison with vascular endothelial growth factor，tumor necrosis factor alpha，and interleukin-1beta-mediated breakdown［J］.J Neurosci Res，1997，49（3）：268-280.
［57］　ISHIDA S，USUI T，YAMASHIRO K，KAJI Y，AHMED E，CARRASQUILLO K G，et al.VEGF164 is proinflammatory in the diabetic retina［J］.Invest Ophthalmol Vis Sci，2003，44（5）：2155-2162.
［58］　CEHOFSKI L J，KRUSE A，MAGNUSDOTTIR S O，ALSING A N，NIELSEN J E，KIRKEBY S，et al.Dexamethasone intravitreal implant downregulates PDGFR-alpha and upregulates caveolin-1 in experimental branch retinal vein occlusion［J］.Exp Eye Res，2018，171：174-182.

相似文献/References:

[1]王刚.曲安奈德联合氪激光治疗视网膜静脉阻塞的临床疗效观察[J].眼科新进展,2013,33(7):000.
[2]马宇 刘意 郭娟 周利晓.金纳多联合血栓通对视网膜静脉阻塞患者同型半胱氨酸水平的影响[J].眼科新进展,2013,33(9):000.
[3]李国兴 韩丽英.曲安奈德玻璃体腔注射治疗黄斑水肿[J].眼科新进展,2008,28(9):000.
[4]袁子茗 王帅 宋蓓雯 胡健艳 吴强.维速达尔光动力疗法诱导兔视网膜静脉阻塞的实验研究[J].眼科新进展,2012,32(9):000.
[5]周正申 孙静芬.白内障超声乳化术后黄斑区光学相干断层扫描观察[J].眼科新进展,2013,33(2):000.
[6]刘广峰 蔺洁 范颖 顾铮 高新晓 朱岩 孟忻 王华 贾宇颂 付秀稳 汪军.非增生型糖尿病视网膜病变黄斑水肿患者黄斑区谱域光学相干断层扫描中高反射信号的特征分析[J].眼科新进展,2013,33(4):000.
[7]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[8]李娟娟 李燕.先天性及获得性视盘血管袢的临床观察[J].眼科新进展,2013,33(11):000.
[9]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[10]徐斌 戴奕娟 梁丽 杨露. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J].眼科新进展,2014,34(2):181.
[11]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[12]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[13]周洁,王宏彬,王文亭.雷珠单抗治疗视网膜静脉阻塞的临床研究[J].眼科新进展,2016,36(1):070.[doi:10.13389/j.cnki.rao.2016.0020]
　ZHOU Jie,WANG Hong-Bin,WANG Wen-Ting.Efficacy of intravitreal injection of ranibizumab for retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(1):070.[doi:10.13389/j.cnki.rao.2016.0020]
[14]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
　WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(1):471.[doi:10.13389/j.cnki.rao.2016.0126]
[15]张敏,朱健华,冯浩,等.视网膜静脉阻塞合并黄斑水肿患者黄斑区微结构改变与视力的相关性分析[J].眼科新进展,2016,36(11):1061.[doi:10.13389/j.cnki.rao.2016.0283]
　ZHANG Min,ZHU Jian-Hua,FENG Hao,et al.Macular microstructure changes in retinal vein occlusion and its correlation with visual acuity[J].Recent Advances in Ophthalmology,2016,36(1):1061.[doi:10.13389/j.cnki.rao.2016.0283]
[16]夏松,陈有信.视网膜静脉阻塞继发黄斑水肿的抗VEGF药物治疗进展[J].眼科新进展,2016,36(11):1093.[doi:10.13389/j.cnki.rao.2016.0292]
　XIA Song,CHEN You-Xin.Research progress on anti-VEGF drugs for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(1):1093.[doi:10.13389/j.cnki.rao.2016.0292]
[17]马为梅,雷晓琴,田芳,等.视网膜静脉阻塞黄斑水肿的多焦视网膜电图与光学相干断层扫描分析[J].眼科新进展,2017,37(7):651.[doi:10.13389/j.cnki.rao.2017.0165]
　MA Wei-Mei,LEI Xiao-Qin,TIAN Fang,et al.Multifocal electroretinogram and optical coherence tomography characteristics of macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2017,37(1):651.[doi:10.13389/j.cnki.rao.2017.0165]
[18]李筱荣,周怀蔚.重视黄斑水肿的病因、治疗及预防[J].眼科新进展,2019,39(7):601.[doi:10.13389/j.cnki.rao.2019.0139]
　LI Xiao-Rong,ZHOU Huai-Yu.Special attention to the cause,treatment and prevention of macular edema[J].Recent Advances in Ophthalmology,2019,39(1):601.[doi:10.13389/j.cnki.rao.2019.0139]
[19]梁婉玲,周怀胜,马海智,等.地塞米松玻璃体内植入剂Ozurdex治疗视网膜静脉阻塞继发黄斑水肿的短期疗效[J].眼科新进展,2019,39(7):666.[doi:10.13389/j.cnki.rao.2019.0153]
　LIANG Wan-Ling,ZHOU Huai-Sheng,MA Hai-Zhi,et al.The short-term efficacy of Ozurdex for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(1):666.[doi:10.13389/j.cnki.rao.2019.0153]
[20]冼志林,梁琦晨,袁洋行,等.地塞米松玻璃体内植入剂Ozurdex治疗视网膜静脉阻塞继发黄斑水肿的研究进展[J].眼科新进展,2020,40(3):296.[doi:10.13389/j.cnki.rao.2020.0069]
　XIAN Zhilin,LIANG Qichen,YUAN Yanghang,et al.Research advances on dexamethasone intravitreal implant Ozurdex for treatment of macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2020,40(1):296.[doi:10.13389/j.cnki.rao.2020.0069]

备注/Memo

备注/Memo:
国家自然科学基金资助（编号：81470650、81670841）；北京市自然科学基金资助（编号：7172218）
更新日期/Last Update: 2020-01-05